Large intramuscular hematoma due to acquired Factor VIII inhibitors in post Polycythemia Vera-Myelofibrosis.

Q4 Health Professions
Clinical hematology international Pub Date : 2025-07-07 eCollection Date: 2025-01-01 DOI:10.46989/001c.141157
Raghuveer S Prabhu, Sarath R V S, Rahmathullah S N
{"title":"Large intramuscular hematoma due to acquired Factor VIII inhibitors in post Polycythemia Vera-Myelofibrosis.","authors":"Raghuveer S Prabhu, Sarath R V S, Rahmathullah S N","doi":"10.46989/001c.141157","DOIUrl":null,"url":null,"abstract":"<p><p>A 59-year-old man with Janus kinase-2 (JAK2) V617F mutation-positive polycythemia vera, evolving to myelofibrosis presented with a right thigh hematoma. Further evaluation showed prolonged activated partial thromboplastin time (aPTT), which was partially corrected after mixing with pooled normal plasma (PNP) and, low factor VIII (F VIII) levels. He was diagnosed to have acquired F VIII inhibitors, and treated with prednisolone for inhibitor eradication. After four weeks of treatment, his aPTT normalized, F VIII rose to 86% and the hematoma was resolved. The case report is followed by a discussion on the topic, revisiting the handful of cases published so far, and the possible mechanisms leading to inhibitor formation in MPN. Further studies are required to elucidate the pathophysiology and the incidence of F VIII inhibitor development in myeloproliferative neoplasms.</p>","PeriodicalId":93942,"journal":{"name":"Clinical hematology international","volume":"7 3","pages":"14-19"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12240161/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical hematology international","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46989/001c.141157","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Health Professions","Score":null,"Total":0}
引用次数: 0

Abstract

A 59-year-old man with Janus kinase-2 (JAK2) V617F mutation-positive polycythemia vera, evolving to myelofibrosis presented with a right thigh hematoma. Further evaluation showed prolonged activated partial thromboplastin time (aPTT), which was partially corrected after mixing with pooled normal plasma (PNP) and, low factor VIII (F VIII) levels. He was diagnosed to have acquired F VIII inhibitors, and treated with prednisolone for inhibitor eradication. After four weeks of treatment, his aPTT normalized, F VIII rose to 86% and the hematoma was resolved. The case report is followed by a discussion on the topic, revisiting the handful of cases published so far, and the possible mechanisms leading to inhibitor formation in MPN. Further studies are required to elucidate the pathophysiology and the incidence of F VIII inhibitor development in myeloproliferative neoplasms.

大肌肉内血肿由于获得性因子VIII抑制剂后的多红细胞增多症-髓纤维化。
一名59岁男性,患有Janus kinase-2 (JAK2) V617F突变阳性真性红细胞增多症,发展为骨髓纤维化,表现为右大腿血肿。进一步的评估显示,活化的部分凝血活素时间(aPTT)延长,在混合正常血浆(PNP)和低因子VIII (fviii)水平后部分纠正。他被诊断为获得fviii抑制剂,并接受强的松龙治疗以根除抑制剂。治疗4周后aPTT恢复正常,fviii升高至86%,血肿消退。病例报告之后是对该主题的讨论,回顾了迄今为止发表的少数病例,以及导致MPN中抑制剂形成的可能机制。需要进一步的研究来阐明fviii抑制剂在骨髓增殖性肿瘤中的病理生理和发生率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.30
自引率
0.00%
发文量
0
审稿时长
20 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信